Praxis' seizure pill fails late-stage study Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 2 June, 2026

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

news Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit Allen Institute launches $200M effort to turn brain atlas lessons into medicines Praxis sinks on late-stage study fail for seizure pill, halts second trial Epigenetic editing shows promise against chronic hep B infections

Jun 11 11:00 am ET Data-driven manufacturing: Enhancing process robustness across sites sponsored by Samsung Biologics

Senior Director, Licensing Officer Bayer Cambridge, MA, USA Director, Government Pricing Sandoz Princeton, NJ, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

PHARMA The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way  Shionogi wins US approval for first pill to prevent Covid following exposure J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain AstraZeneca's triplet combo succeeds in some liver cancer patients ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

in case you missed it 1. Lilly enters GLP-2 space in deal with Korea's Hanmi, also forges discovery pact with China's Haisco 2. Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets 3. Kelonia Therapeutics delivers impressive in vivo CAR-T update 4. After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing 5. Oculis’ eye drops for diabetic macular edema flunk Phase 3 test 6. Turn Therapeutics' eczema drug shows rapid response in mid-stage data 7. News Briefing